The global market for anticoagulants was estimated at US$33,150.7 million in 2017 and expected to grow at a compound annual growth rate (CAGR) of 6.6% over the forecast period from 2018 to 2026.

SANJOSE, United States - March 7, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. Anticoagulants Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026, the global anticoagulants market was valued at US$ 33,150.7 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 6.6% during the forecast period from 2018 to 2026.

Market Insights

The global anticoagulants market is projected to grow at a steady rate during the forecast period attributable to launch of drugs with lower side effects and higher efficacy, growing prevalence of cardiovascular diseases globally and higher adoption of novel oral anticoagulants (NOACs) in North America and Europe. Promising pipeline will further drive the market during the forecast period. For instance, Ionis Pharmaceutical is developing a novel antisense drug named IONIS- FXIRx that is designed to reduce the production of coagulation factor XI that plays a key role in proliferation of clots. The drug is in phase II of clinical trials and claims to have positive results when tested in patients undergoing replacement to prevent venous thrombosis. Espero Biopharma phase III candidate, a vitamin K antagonist named Tecarfarin claims of having fewer adverse effects and lesser drug-drug interaction as compared to warfarin. Thus, these promising drug candidates will drive the market in the latter stage of the forecast period.

Browse full report at https://www.credenceresearch.com/report/anticoagulants-market

In terms of application, the market is segmented into atrial fibrillation & heart attacks, strokes, deep vein thrombosis (DVT), and pulmonary embolism. In 2017, atrial fibrillation (AF) & heart attacks held the largest share in the anticoagulants market owing to large target population of patients suffering from atrial fibrillation and growing incidence of heart attacks. According to recent study in Britain, it is estimated that 1.4 million British people at a high risk of strokes due to non-valvular atrial fibrillation (NVAF). AF prevalence is higher in North America and Asia Pacific, thereby driving the market due to increased usage of anticoagulants. Deep vein thrombosis is expected to show significant growth rate during the forecast period, due to growing cases and products specifically targeting DVT.

In terms of geography, North America held the largest share of over 48% in the global anticoagulants market. The increasing usage of NOACs in the region is the major driving factor for the growth of the market. Xarelto and Eliquis are the most prescribed drugs in the U.S. followed by warfarin. Structured approval policies by the U.S. Food and Drug Administration (FDA) and efficient reimbursement scenario drive the market in North America. Asia Pacific emerged as the fastest growing region owing to high target population, lucrative opportunities for foreign players to invest in and ever-growing prevalence of cardiovascular diseases. Furthermore, growing number of pharmaceutical players indulging in research & development of anticoagulants and growing health awareness will further drive the market. The key players currently engaged in anticoagulants market include Bayer AG, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pfizer, Inc., Daiichi Sankyo Company Limited, and Portola Pharmaceuticals, Inc. among others.

Get Sample @ https://www.credenceresearch.com/sample-request/59614

Key Market Movements:

Promising pipeline for anticoagulants in North America and Europe to drive the market during the forecast period
Growing research and development by pharmaceutical players further boost market growth
Rising prevalence of cardiovascular disease such as atrial fibrillation, DVT and coronary heart diseases

ToC:
Chapter 3. Anticoagulants: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Anticoagulants Market, by Key Players, 2017

Chapter 4. Global Anticoagulants Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Novel Oral Anticoagulants (NOACs)
4.3. Vitamin K Antagonists
4.4. Heparins & Low Molecular Weight Heparins (LMWH)
4.5. Antiplatelet Agents
4.6. Thrombolytic Agents
4.7. Direct Thrombin Inhibitors
4.8. Pipeline Analysis (Forecast for Phase III drugs till 2026)

Chapter 5. Global Anticoagulants Market, by Application Type, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Atrial Fibrillation & Heart Attacks
5.3. Strokes
5.4. Deep Vein Thrombosis (DVT)
5.5. Pulmonary Embolism
...........
...............
Chapter 7. Company Profiles
7.1. Boehringer Ingelheim Internation GmbH
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Bayer AG
7.3. Johnson & Johnson, Inc.
7.4. Bristol-Myers Squibb Company
7.5. Pfizer, Inc.
7.6. Daiichi-Sankyo Company Limited
7.7. Portola Pharmaceuticals, Inc.
7.8. Sanofi S.A.
7.9. Aspen Holdings
7.10. GlaxoSmithKline Plc
.................toc continued

Browse full report at https://www.credenceresearch.com/report/anticoagulants-market

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/anticoagulants-market-share-and-growth-2018-2026-explored-in-latest-research/489565

Source: MarketersMedia

Release ID: 489565